Published in JAMA on September 17, 2003
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature (2011) 13.53
Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA (2014) 3.27
Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol (2009) 3.09
Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J (2012) 2.09
Infectious burden and risk of stroke: the northern Manhattan study. Arch Neurol (2009) 2.08
Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J (2012) 1.71
"Gum bug, leave my heart alone!"--epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis. J Dent Res (2010) 1.61
Pneumococcal vaccination and risk of myocardial infarction. CMAJ (2008) 1.61
Immunity, atherosclerosis and cardiovascular disease. BMC Med (2013) 1.49
Influenza and cardiovascular disease: is there a causal relationship? Tex Heart Inst J (2004) 1.39
Correlation of drug utilisation and morbidity at the municipality level. High use of antibiotics associated with low use of antihypertensives. Eur J Clin Pharmacol (2006) 1.38
T-cell costimulation and coinhibition in atherosclerosis. Circ Res (2008) 1.32
Infectious burden and carotid plaque thickness: the northern Manhattan study. Stroke (2010) 1.14
Antibiotic therapy for coronary artery disease: can a WIZARD change it all? JAMA (2003) 1.05
Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med (2014) 0.98
Infection and Atherosclerosis Development. Arch Med Res (2015) 0.96
The relationship between periodontitis and systemic diseases - hype or hope? J Clin Diagn Res (2013) 0.96
Chlamydophila pneumoniae infection and cardiovascular disease. N Am J Med Sci (2013) 0.95
Persistent C. pneumoniae infection in atherosclerotic lesions: rethinking the clinical trials. Front Cell Infect Microbiol (2014) 0.95
Immune mechanisms in atherosclerosis, especially in diabetes type 2. Front Endocrinol (Lausanne) (2013) 0.94
Role of gut microbiota in atherosclerosis. Nat Rev Cardiol (2016) 0.90
Infectious burden: a new risk factor and treatment target for atherosclerosis. Infect Disord Drug Targets (2010) 0.89
The gut microbiota, environment and diseases of modern society. Gut Microbes (2012) 0.88
Toll-like Receptors in the Vascular System: Sensing the Dangers Within. Pharmacol Rev (2016) 0.84
Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial. J Clin Microbiol (2005) 0.83
Antibiotic trials for coronary heart disease. Tex Heart Inst J (2004) 0.83
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells. Antimicrob Agents Chemother (2004) 0.82
Porphyromonas gingivalis-dendritic cell interactions: consequences for coronary artery disease. J Oral Microbiol (2010) 0.82
Pro-atherogenic lung and oral pathogens induce an inflammatory response in human and mouse mast cells. J Cell Mol Med (2009) 0.81
Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice. Antimicrob Agents Chemother (2004) 0.81
Acute coronary syndrome and chronic infection in the Cork coronary care case-control study. Heart (2005) 0.81
Periodontitis and coronary artery disease: a questioned association between periodontal and vascular plaques. Am J Cardiovasc Dis (2011) 0.80
Is C. Pneumoniae research in peril? Front Microbiol (2011) 0.80
Current understanding of the relationship between periodontal and systemic diseases. Saudi Med J (2015) 0.79
Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested. Pathog Dis (2014) 0.78
Oral azithromycin in extended dosage schedule for chronic, subclinical Chlamydia pneumoniae infection causing coronary artery disease: a probable cure in sight? Results of a controlled preliminary trial. Int J Gen Med (2012) 0.78
Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction. Eur J Clin Pharmacol (2005) 0.78
Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. Clin Res Cardiol (2014) 0.78
Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf (2014) 0.76
New perspectives of infections in cardiovascular disease. Curr Cardiol Rev (2009) 0.76
A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases. Can J Cardiol (2008) 0.76
Supra-additive expression of interleukin-6, interleukin-8 and basic fibroblast growth factor in vascular smooth muscle cells following coinfection with Chlamydia pneumoniae and cytomegalovirus as a novel link between infection and atherosclerosis. Can J Infect Dis Med Microbiol (2012) 0.76
Antibiotics and coronary heart disease. JAMA (2004) 0.75
The immune system in atherosclerosis and in acute myocardial infarction. Heart Int (2006) 0.75
Impact of seropositivity to Chlamydia pneumoniae and anti-hHSP60 on cardiovascular events in hemodialysis patients. Cell Stress Chaperones (2010) 0.75
Chlamydial bacteriophage: No role in acute coronary events? Can J Infect Dis Med Microbiol (2005) 0.75
Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. Am Health Drug Benefits (2014) 0.75
Antibiotics and coronary heart disease. JAMA (2004) 0.75
Azithromycin ineffective for secondary coronary heart disease. J Fam Pract (2004) 0.75
The Role of Unknown Risk Factors in Myocardial Infarction. Cardiol Res (2010) 0.75
Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death? Can J Hosp Pharm (2013) 0.75
Helicobacter pylori infection and atherosclerosis: is there a causal relationship? Eur J Clin Microbiol Infect Dis (2017) 0.75
Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. Drug Saf (2017) 0.75
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med (2014) 5.05
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol (2010) 4.27
Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med (2014) 3.86
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. Circulation (2006) 3.76
Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med (2009) 3.73
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Azithromycin for the secondary prevention of coronary events. N Engl J Med (2005) 3.42
Controversies in ventricular remodelling. Lancet (2006) 3.39
Heart failure. Lancet (2005) 3.33
A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation (2012) 3.30
Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol (2005) 3.13
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation (2011) 2.62
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease. Circ Cardiovasc Genet (2008) 2.50
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation (2007) 2.41
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol (2007) 2.40
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation (2005) 2.39
Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation (2003) 2.36
Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation (2004) 2.33
Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction. J Am Coll Cardiol (2010) 2.29
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging (2008) 2.24
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension (2007) 2.22
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 2.21
Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med (2004) 2.13
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation (2005) 2.13
Usefulness of routine periodic fasting to lower risk of coronary artery disease in patients undergoing coronary angiography. Am J Cardiol (2008) 2.10
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis (2011) 2.05
Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation (2003) 2.03
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation (2006) 2.01
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation (2010) 2.00
Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies. Circ Res (2011) 1.98
Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm (2009) 1.95
Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation (2002) 1.93
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail (2009) 1.93
Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol (2002) 1.87
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation (2011) 1.87
Augmentation index and central aortic stiffness in middle-aged to elderly individuals. Am J Hypertens (2007) 1.85
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J (2008) 1.84
Irbesartan in patients with atrial fibrillation. N Engl J Med (2011) 1.84
Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population. Clin Chim Acta (2011) 1.83
Management of ingested magnets in children. J Pediatr Gastroenterol Nutr (2012) 1.78
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis (2006) 1.78
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol (2007) 1.76
Incremental survival benefit with adherence to standardized heart failure core measures: a performance evaluation study of 2958 patients. J Card Fail (2008) 1.74
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 1.69
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst (2012) 1.68
Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med (2009) 1.67
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J Biol Chem (2006) 1.65
Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol (2013) 1.65
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62
Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database. Am Heart J (2006) 1.60
Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial--Cardiac Resynchronization Therapy (MADIT-CRT). Heart Rhythm (2010) 1.60
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation (2005) 1.59
Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation (2002) 1.57
C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol (2002) 1.56
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol (2012) 1.55
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. Eur J Heart Fail (2010) 1.55